Clinical Trial Detail

NCT ID NCT03526432
Title Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors University of Oklahoma
Indications

endometrial carcinoma

Therapies

Atezolizumab + Bevacizumab

Age Groups: adult senior

No variant requirements are available.